Moody’s Downgrades AstraZeneca to A2 as Loses Patent Protection

AstraZeneca Plc’s long-term senior unsecured debt rating was cut by Moody’s Investors Service to A2 from A1 on concern that earnings and sales will be hurt as it loses patent protection on some of its best-selling medicines.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.